Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17367 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Mickaël Machicoane und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fastox Pharma SA, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Junction. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fastox Pharma, Università degli Studi di Padova, Italian Ministry of University and Research.
Abstract (Originalsprache)
Background and Purpose Botulinum neurotoxin type A1 (BoNT/A) is one of the most potent neurotoxins known. At the same time, it is also one of the safest therapeutic agents used for the treatment of several human disorders and in aesthetic medicine. Notwithstanding great effectiveness, strategies to accelerate the onset and prolong BoNT/A action would significantly ameliorate its pharmacological effects with beneficial outcomes for clinical use. Experimental Approach Here, we combined BoNT/A with two fast‐acting inhibitors of excitation–contraction coupling inhibitors (ECCI), either the μ‐conotoxin CnIIIC or dantrolene, and tested the effect of their co‐injection on a model of hind‐limb paralysis in rodents using behavioural, biochemical, imaging and electrophysiological assays. Key Results The BoNT/A‐ECCI combinations accelerated the onset of muscle relaxation. Surprisingly, they also potentiated the peak effect and extended the duration of the three BoNT/A commercial preparations OnabotulinumtoxinA, AbobotulinumtoxinA and IncobotulinumtoxinA. ECCI co‐injection increased the number of BoNT/A molecules entering motoneuron terminals, which induced a faster and greater cleavage of SNAP‐25 during the onset and peak phases, and prolonged the attenuation of nerve‐muscle neurotransmission during the recovery phase. We estimate that ECCI co‐injection yields a threefold potentiation in BoNT/A pharmacological activity. Conclusions and Implications Overall, our results show that the pharmacological activity of BoNT/A can be combined and synergized with other bioactive molecules and uncover a novel strategy to enhance the neuromuscular effects of BoNT/A without altering the neurotoxin moiety or intrinsic activity, thus maintaining its exceptional safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fastox Pharma SA, Lausanne, Switzerland.
- Department of Biomedical Sciences, University of Padova, Padova, Italy.
- Padova Neuroscience Center, University of Padova, Padova, Italy.
- Institute of Neuroscience, Italian Research Council, University of Padova, Padova, Italy.
- Interdepartmental Research Center of Myology CIR-Myo, University of Padova, Padova, Italy.
ORCID-Profile: Marco Pirazzini
Förderung
- Fastox Pharma
- Università degli Studi di Padova
- Italian Ministry of University and Research
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Machicoane, M., Tonellato, M., Zainotto, M., Onillon, P., Stazi, M., Corso, M. D., Megighian, A., Rossetto, O., Le Doussal, J. M., & Pirazzini, M. (2025). Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction. British Journal of Pharmacology. https://doi.org/10.1111/bph.17367
Vancouver
Machicoane M, Tonellato M, Zainotto M, Onillon P, Stazi M, Corso MD, et al. Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction. British Journal of Pharmacology. 2025. doi:10.1111/bph.17367
BibTeX
@article{Machicoane2025,
author = {Machicoane, Mickaël and Tonellato, Marika and Zainotto, Marica and Onillon, Paul and Stazi, Marco and Corso, Mattia Dal and Megighian, Aram and Rossetto, Ornella and Le Doussal, Jean-Marc and Pirazzini, Marco},
title = {Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17367}
}
EUVIMED